Document Detail


Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos.
MedLine Citation:
PMID:  9493648     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Bromocriptine, which is used in the treatment of Parkinson's disease, can cause adverse pleuropulmonary reactions. Exposure to asbestos can result in similar lesions. Fifteen patients with former exposure to asbestos, who developed pleural fibrosis after treatment with bromocriptine, were observed independently in Sweden (11 patients) and Australia (four patients). The patients complained of malaise, often associated with weight loss, dyspnoea, and a disturbing cough. Laboratory values included increased erythrocyte sedimentation rate and a low haemoglobin level. Lung function tests showed a restrictive lung function defect. Chest radiographs showed bilateral pleural fibrosis, with small amounts of fluid in some cases. Soon after bromocriptine was withdrawn, the patients improved clinically, and the laboratory values returned to normal. However, in most cases, pleural fibrosis and a restrictive lung function defect persisted to some extent. In conclusion, in patients who develop pleuropulmonary fibrosis whilst being treated with bromocriptine, former exposure to asbestos should be investigated. Conversely, when pleural changes develop in a patient on bromocriptine and with prior exposure to asbestos, the possible causative role of the drug should be discussed. Special follow-up may be indicated when bromocriptine is planned in a patient with previous asbestos exposure, and if symptoms or signs of pleural fibrosis develop, bromocriptine withdrawal should be considered.
Authors:
G Hillerdal; J Lee; A Blomkvist; A Rask-Andersen; M Uddenfeldt; H Koyi; E Rasmussen
Related Documents :
2543248 - Urinary neopterin in pulmonary sarcoidosis. relationship to clinical and biologic asses...
20237928 - Intravenous immunoglobulin therapy leading to dramatic improvement in a patient with sy...
6363798 - A controlled study of the effect of indomethacin in uremic pericarditis.
3014958 - Assessment of gallium-67 scanning in pulmonary and extrapulmonary sarcoidosis.
12560878 - Assessment of lumbar spinal canal stenosis by magnetic resonance phlebography.
25262398 - Patients with mucopolysaccharidosis have tendencies towards vertical facial growth.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  The European respiratory journal     Volume:  10     ISSN:  0903-1936     ISO Abbreviation:  Eur. Respir. J.     Publication Date:  1997 Dec 
Date Detail:
Created Date:  1998-04-23     Completed Date:  1998-04-23     Revised Date:  2013-05-23    
Medline Journal Info:
Nlm Unique ID:  8803460     Medline TA:  Eur Respir J     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  2711-5     Citation Subset:  IM    
Affiliation:
Dept of Lung Medicine, Karolinska Hospital, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Antiparkinson Agents / adverse effects*,  therapeutic use
Asbestos / adverse effects*
Bromocriptine / adverse effects*,  therapeutic use
Bronchoalveolar Lavage
Cohort Studies
Environmental Monitoring
Epidemiological Monitoring
Follow-Up Studies
Humans
Middle Aged
Occupational Exposure / adverse effects*
Parkinson Disease / complications,  drug therapy
Pleural Diseases / epidemiology,  etiology*,  radiography
Pulmonary Fibrosis / epidemiology,  etiology*,  radiography
Respiratory Function Tests
Risk Factors
Chemical
Reg. No./Substance:
0/Antiparkinson Agents; 1332-21-4/Asbestos; 25614-03-3/Bromocriptine
Comments/Corrections
Comment In:
Eur Respir J. 1997 Dec;10(12):2695-8   [PMID:  9493644 ]
Eur Respir J. 1998 Jun;11(6):1427   [PMID:  9657590 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The birth and development of the forced expiratory manoeuvre: a tribute to Robert Tiffeneau (1910-19...
Next Document:  The CD4/CD8 ratio in BAL fluid is highly variable in sarcoidosis.